Merck and Palantir to form JV to advance cancer research
Nov 20, 2018 - Marketline Newswire
Merck has signed a non-binding term sheet to establish a joint venture (JV) with data analytics firm Palantir Technologies to support the advancement of cancer research.
The JV will be known as Syntropy and will focus on empowering scientists and research centres with data integration, as well as analytics technology to advance cancer research.Syntropy intends to provide scientists access to biomedical data available with global research institutions and facilitate the collaboration of exp...
Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.
Are you ready to take your business development to the next level with RelSci Professional?
Nurture your network with daily alerts that notify you when your relationships make news
Map your relationships to any target or prospect to identify a warm introduction
Access unlimited deep dossiers on over 8 million decision makers
Best of all, you can try out all these powerful business development tools absolutely free for 30 days!
Check out News Home to stay on top of the people and organizations you care most about.
